Liquidia Corp (LQDA): Capital Expenditures
$4.34M
Year ended 2025-12-31
$17.01M
Trailing 12 months to 2026-06-30
+94.2%
3-year compound annual growth
+42.0%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $4.34M | -12.4% | 2026-03-05, From 2025-01-01 |
| 2024-12-31 | $4.95M | +283.6% | 2026-03-05, From 2024-01-01 |
| 2023-12-31 | $1.29M | +117.9% | 2026-03-05, From 2023-01-01 |
| 2022-12-31 | $592.0K | +453.3% | 2024-03-13, From 2022-01-01 |
| 2021-12-31 | $107.0K | -85.8% | 2023-03-20, From 2021-01-01 |
| 2020-12-31 | $752.1K | -59.3% | 2022-03-17, From 2020-01-01 |
| 2019-12-31 | $1.85M | n/a | 2021-03-25, From 2019-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Liquidia Corp (LQDA) | 2025-12-31 | $4.34M | -12.4% |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | $317.0K | -81.4% |
| Macrogenics Inc (MGNX) | 2025-12-31 | $1.91M | -48.4% |
| Elite Pharmaceuticals Inc (ELTP) | 2026-03-31 | $925.6K | -43.0% |
| Karyopharm Therapeutics Inc. (KPTI) | 2025-12-31 | $0 | -100.0% |
| Syndax Pharmaceuticals Inc (SNDX) | 2025-12-31 | $187.0K | n/a |
| Phathom Pharmaceuticals, Inc. (PHAT) | 2025-12-31 | $229.0K | +69.6% |
| Cryoport, Inc. (CYRX) | 2025-12-31 | $16.44M | -4.7% |
| Lifevantage Corp (LFVN) | 2026-06-30 | $3.57M | +160.5% |
Compare LQDA, HRTX, MGNX, ELTP side by side · Screen every company in Pharmaceutical Preparations ↗